潜在转化生长因子β结合蛋白2在乳腺癌中的表达及其临床意义

The expression of LTBP2 in breast cancer and its clinical significance

目的通过对乳腺癌及癌旁正常乳腺组织中潜在转化生长因子β结合蛋白2（LTBP2）的表达的检测，探讨LTBP2在乳腺癌发生、发展及侵袭过程中所起的作用及其作为乳腺癌预后标志物的价值。方法收集南通大学附属医院病理科2010年1月—2011年12月间125例乳腺癌组织及癌旁正常乳腺组织，免疫组化法检测LTBP2的表达情况，分析LTBP2蛋白表达与雌激素受体（ER）、孕激素受体（PR）、Ki67及人表皮生长因子受体（HER）2的关系及其与乳腺癌临床病理参数间的联系。结果LTBP2蛋白在乳腺癌（55．20％）的阳性表达率明显高于癌旁正常乳腺组织（28．80％）（P〈0．001）。乳腺癌组织中LTBP2的表达与临床分期（χ^2=4．516，P=0．034）、ER（χ^2=7．112，P=0．008）与Ki67（χ^2=4．024，P=0．045）过表达等不良预后因素相关。讨论乳腺癌组织中LTBP2呈阳性表达，可能成为评估预后的标志物，在乳腺癌发生与发展中可能起到重要作用。

Objective To explore the expression of latent transforming growth factor （TGF）-beta binding protein 2 （LTBP2） in breast cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression of LTBP2 in 125 cases of breast cancer tissue and nolmal breast tissue. Relationship between the expression of LTBP2 and estrogen receptor （ER） , progesterone receptor （PR） , human epidermal growth factor receptor 2 （ HER2 ）, Ki67, and its relationship with clinicopathological parameters of breast cancer were analyzed. Results The positive expression of LTBP2 in breast cancer tissues （ 55.20% ） was significantly higher than that in adjacent normal breast tissues （ 28.80% ） （ P 〈 0. 001 ）. The expression of LTBP2 in breast cancer tissues was correlated with the clinical stage （χ^2 = 4. 516,P = 0. 034）, over-expression of ER （ χ^2= 7. 112,P = 0. 008 ） and Ki67 （ χ^2 = 4. 024,P = 0. 045 ） and other adverse prognostic factors. Conclusion Positive expression of LTBP2 in breast cancer plays an important role in the development and progression of breast cancer, and may be a marker of prognosis of patients.